

K Rajender Reddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4740700/publications.pdf>

Version: 2024-02-01

319
papers

41,529
citations

4641

85
h-index

2375

198
g-index

348
all docs

348
docs citations

348
times ranked

24163
citing authors

#	ARTICLE	IF	CITATIONS
1	Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 2002, 347, 975-982.	13.9	6,268
2	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine, 2011, 364, 1195-1206.	13.9	2,352
3	Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 2011, 364, 2405-2416.	13.9	2,278
4	Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. New England Journal of Medicine, 2013, 368, 1878-1887.	13.9	1,605
5	Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection. New England Journal of Medicine, 2014, 370, 1483-1493.	13.9	1,241
6	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. New England Journal of Medicine, 2014, 370, 1879-1888.	13.9	1,080
7	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. New England Journal of Medicine, 2014, 370, 211-221.	13.9	1,065
8	Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology, 2008, 134, 1752-1763.	0.6	994
9	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, 149, 649-659.	0.6	725
10	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. New England Journal of Medicine, 2015, 373, 2618-2628.	13.9	692
11	ABT-450/Ombitasvir and Dasabuvir with or without Ribavirin for HCV. New England Journal of Medicine, 2014, 370, 1983-1992.	13.9	669
12	Î±-Fetoprotein, Des-Î³ Carboxyprothrombin, and Lectin-Bound Î±-Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterology, 2009, 137, 110-118.	0.6	644
13	American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology, 2015, 148, 215-219.	0.6	634
14	Grazoprevir/Elbasvir Combination Therapy for Treatment-Naïve Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection. Annals of Internal Medicine, 2015, 163, 1-13.	2.0	501
15	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. Journal of Hepatology, 2005, 43, 425-433.	1.8	484
16	Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon Î±-2a (40) Tj ETQq0 0 0 rgBT/Overlock, 10 Tf 50 1	3.6	469
17	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. New England Journal of Medicine, 2017, 376, 2134-2146.	13.9	467
18	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology, 2014, 60, 250-256.	3.6	456

#	ARTICLE	IF	CITATIONS
19	Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 124-129.	2.4	446
20	The North American Study for the Treatment of Refractory Ascites. <i>Gastroenterology</i> , 2003, 124, 634-641.	0.6	424
21	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. <i>Hepatology</i> , 2020, 72, 287-304.	3.6	408
22	Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). <i>Journal of Hepatology</i> , 2002, 37, 500-506.	1.8	388
23	Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , 2012, 56, 2328-2335.	3.6	357
24	Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy. <i>Annals of Internal Medicine</i> , 1996, 125, 634.	2.0	335
25	Efficacy and safety of pegylated (40-kd) interferon α -2a compared with interferon α -2a in noncirrhotic patients with chronic hepatitis C. <i>Hepatology</i> , 2001, 33, 433-438.	3.6	317
26	Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. <i>New England Journal of Medicine</i> , 2017, 376, 2394-2395.	13.9	315
27	Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 401-408.	4.6	313
28	Immune Dysfunction and Infections in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 727-738.	2.4	299
29	Racial differences in responses to therapy with interferon in chronic hepatitis C. <i>Hepatology</i> , 1999, 30, 787-793.	3.6	293
30	Outcomes in Adults With Acute Liver Failure Between 1998 and 2013. <i>Annals of Internal Medicine</i> , 2016, 164, 724.	2.0	279
31	Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. <i>Hepatology</i> , 2004, 39, 1702-1708.	3.6	264
32	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. <i>Gastroenterology</i> , 2016, 150, 1590-1598.	0.6	253
33	Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. <i>Lancet</i> , The, 2015, 385, 2502-2509.	6.3	245
34	Review article: herbal and dietary supplement hepatotoxicity. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 3-17.	1.9	243
35	Acetaminophen-related Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2013, 17, 587-607.	1.0	237
36	Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. <i>New England Journal of Medicine</i> , 2021, 384, 818-828.	13.9	235

#	ARTICLE	IF	CITATIONS
37	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , 2015, 62, 79-86.	3.6	232
38	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. <i>Gastroenterology</i> , 2016, 150, 1579-1589.e2.	0.6	225
39	Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 571-586.	6.6	221
40	New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection. <i>Gastroenterology</i> , 2013, 145, 1280-1288.e1.	0.6	221
41	NACSELD acute-to-chronic liver failure (NACSELD-to-CLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2018, 67, 2367-2374.	3.6	197
42	Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients. <i>Annals of Internal Medicine</i> , 2018, 169, 273-281.	2.0	193
43	The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , 2016, 64, 200-208.	3.6	189
44	Idiosyncratic Drug-Induced Liver Injury Is Associated With Substantial Morbidity and Mortality Within 6 Months From Onset. <i>Gastroenterology</i> , 2014, 147, 96-108.e4.	0.6	188
45	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , 2021, 70, 531-536.	6.1	178
46	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
47	Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-±b. <i>Annals of Internal Medicine</i> , 2009, 150, 528.	2.0	162
48	Controlled-Release, Pegylation, Liposomal Formulations: New Mechanisms in the Delivery of Injectable Drugs. <i>Annals of Pharmacotherapy</i> , 2000, 34, 915-923.	0.9	158
49	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018, 68, 1298-1307.	3.6	158
50	Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. <i>Liver Transplantation</i> , 2005, 11, 1048-1055.	1.3	151
51	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-ARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	3.6	149
52	American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. <i>Hepatology</i> , 2021, 74, 1049-1064.	3.6	136
53	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 531-538.	1.1	135
54	Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 274.	3.8	134

#	ARTICLE	IF	CITATIONS
55	Effect of Kidney Transplantation on Outcomes among Patients with Hepatitis C. <i>Journal of the American Society of Nephrology</i> : JASN, 2011, 22, 1152-1160.	3.0	128
56	Acetaminophen (APAP or N-Acetyl-p-Aminophenol) and Acute Liver Failure. <i>Clinics in Liver Disease</i> , 2018, 22, 325-346.	1.0	128
57	Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 674-696.	1.9	127
58	Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 64-77.	1.9	126
59	Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. <i>American Journal of Gastroenterology</i> , 2002, 97, 2117-2119.	0.2	125
60	Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 434-449.	1.0	125
61	Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2008, 46, 78-84.	2.9	123
62	Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 689-699.	0.9	123
63	Viral pathogenesis of hepatocellular carcinoma in the United States. <i>Hepatology</i> , 1993, 18, 1326-1333.	3.6	121
64	Large cystic lesions of the liver in adults: a 15-year experience in a tertiary center. <i>Journal of the American College of Surgeons</i> , 2001, 193, 36-45.	0.2	121
65	Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. <i>American Surgeon</i> , 2001, 67, 173-8.	0.4	116
66	Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis. <i>Hepatology</i> , 2000, 32, 1265-1271.	3.6	114
67	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. <i>Clinical Infectious Diseases</i> , 2021, 72, e558-e565.	2.9	114
68	Utility of Lens culinaris Agglutinin-Reactive Fraction of α -Fetoprotein and Des-Gamma-Carboxy Prothrombin, Alone or in Combination, as Biomarkers for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 104-113.	2.4	113
69	Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2007, 102, 2196-2205.	0.2	112
70	Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1035-1043.	2.4	111
71	Viral pathogenesis of hepatocellular carcinoma in the United States. <i>Hepatology</i> , 1993, 18, 1326-33.	3.6	111
72	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017, 24, 823-831.	1.0	107

#	ARTICLE	IF	CITATIONS
73	Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2423-2429.	1.1	106
74	Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 753-759.e2.	2.4	105
75	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 565-574.e4.	2.4	105
76	Review article: <scp>HCV</scp> genotype 3 â€“ the new treatment challenge. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 686-698.	1.9	103
77	Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. <i>Gastroenterology</i> , 2010, 139, 1602-1611.e1.	0.6	102
78	The Natural History of Severe Acute Liver Injury. <i>American Journal of Gastroenterology</i> , 2017, 112, 1389-1396.	0.2	101
79	Interferonâ€free therapy for genotype 1 hepatitis C in liver transplant recipients: Realâ€world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016, 22, 24-33.	1.3	100
80	Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. <i>Journal of Hepatology</i> , 2004, 41, 1062-1064.	1.8	98
81	Death and liver transplantation within 2 years of onset of drugâ€induced liver injury. <i>Hepatology</i> , 2017, 66, 1275-1285.	3.6	96
82	Population-Representative Incidence of Drug-Induced Acute Liver Failure Based on an Analysis of an Integrated Health Care System. <i>Gastroenterology</i> , 2015, 148, 1353-1361.e3.	0.6	90
83	Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the <scp>OT</scp>â€0401 and <scp>REVERSE</scp> randomised clinical studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1390-1402.	1.9	90
84	Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2007, 102, 880-889.	0.2	89
85	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 756-765.e3.	2.4	89
86	Transplantation: Impact of pretransplant renal insufficiency. <i>Liver Transplantation</i> , 2008, 14, 665-671.	1.3	88
87	Transplanting hepatitis C virusâ€infected hearts into uninfected recipients: A single-arm trial. <i>American Journal of Transplantation</i> , 2019, 19, 2533-2542.	2.6	88
88	Amoxicillin-clavulanate potassium-associated cholestasis. <i>Gastroenterology</i> , 1989, 96, 1135-1141.	0.6	87
89	Extrahepatic manifestations of chronic viral hepatitis. <i>Current Gastroenterology Reports</i> , 2001, 3, 71-78.	1.1	86
90	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. <i>Journal of Hepatology</i> , 2015, 62, 286-293.	1.8	86

#	ARTICLE	IF	CITATIONS
91	Acute-to-Chronic Liver Failure: Getting Ready for Prime Time?. <i>Hepatology</i> , 2018, 68, 1621-1632.	3.6	86
92	Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1728.	3.8	85
93	Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. <i>American Journal of Gastroenterology</i> , 2015, 110, 1450-1459.	0.2	85
94	The Evolving Challenge of Infections in Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 384, 2317-2330.	13.9	85
95	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	1.8	85
96	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015, 62, 25-30.	3.6	82
97	Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , 2012, 61, 1219-1225.	6.1	81
98	Outcomes after liver transplantation: Chronic kidney disease. <i>Liver Transplantation</i> , 2009, 15, S70-S74.	1.3	79
99	Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. <i>Liver Transplantation</i> , 2016, 22, 505-515.	1.3	79
100	Hepatotoxicity of hypolipidemic drugs. <i>Clinics in Liver Disease</i> , 2003, 7, 415-433.	1.0	77
101	Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. <i>Clinical and Experimental Metastasis</i> , 1997, 15, 509-518.	1.7	76
102	A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 217-224.	3.6	74
103	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	1.3	73
104	A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2597-2605.e4.	2.4	73
105	Approach to a Liver Mass. <i>Seminars in Liver Disease</i> , 1993, 9, 423-435.	1.8	72
106	Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. <i>Hepatology</i> , 2004, 40, 892-899.	3.6	72
107	Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 527-536.	1.9	71
108	Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 408-418.	1.0	69

#	ARTICLE	IF	CITATIONS
109	Emricasan (IDN6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. <i>Hepatology</i> , 2019, 69, 717-728.	3.6	68
110	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> , 2022, 54, 761-771.	9.4	68
111	Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. <i>American Journal of Gastroenterology</i> , 2017, 112, 1103-1110.	0.2	67
112	National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1939-1951.	3.0	67
113	Acute-on-Chronic Liver Failure Before Liver Transplantation: Impact on Posttransplant Outcomes. <i>Transplantation</i> , 2011, 92, 952-957.	0.5	66
114	Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. <i>American Journal of Medicine</i> , 2016, 129, 283-291.e5.	0.6	65
115	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , 2020, 159, 1715-1730.e12.	0.6	65
116	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the <sc>US</sc> â€“ the <sc>ENUMERATE</sc> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 134-144.	1.9	63
117	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 173-182.e7.	2.4	62
118	Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1278-1287.	1.9	61
119	Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. <i>Lancet Infectious Diseases</i> , 2015, 15, 27-35.	4.6	60
120	High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end-stage liver disease. <i>Liver Transplantation</i> , 2015, 21, 881-888.	1.3	59
121	Pruritus in Chronic Cholestatic Liver Disease. <i>Clinics in Liver Disease</i> , 2012, 16, 331-346.	1.0	58
122	Drug Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2017, 21, 115-134.	1.0	58
123	An Immunoassay to Rapidly Measure Acetaminophen Protein Adducts Accurately Identifies Patients With Acute Liver Injury or Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 555-562.e3.	2.4	58
124	Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hyâ€™s Law and a New Prognostic Model. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2360-2368.	2.4	57
125	Quality of life in refractory ascites: Transjugular intrahepatic portal-systemic shunting versus medical therapy. <i>Hepatology</i> , 2005, 42, 635-640.	3.6	55
126	Drug-Induced Liver Injury due to Cancer Chemotherapeutic Agents. <i>Seminars in Liver Disease</i> , 2014, 34, 162-171.	1.8	55

#	ARTICLE	IF	CITATIONS
127	Safety and efficacy of ledipasvir–sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. <i>Hepatology</i> , 2016, 63, 437-444.	3.6	55
128	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , 2019, 25, 870-880.	1.3	55
129	All–oral direct–acting antiviral therapy in <scp>HCV</scp>–advanced liver disease is effective in real–world practice: observations through <scp>HCV</scp>–<scp>TARGET</scp> database. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 115-126.	1.9	54
130	Ribavirin: Current role in the optimal clinical management of chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 50, 402-411.	1.8	53
131	Current Management of Hepatocellular Carcinoma. <i>Medical Clinics of North America</i> , 2009, 93, 885-900.	1.1	53
132	Outcomes After Listing for Liver Transplant in Patients With Acute–on–Chronic Liver Failure: The Multicenter North American Consortium for the Study of End–Stage Liver Disease Experience. <i>Liver Transplantation</i> , 2019, 25, 571-579.	1.3	53
133	Risk factors for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 180-182.	1.0	52
134	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection–A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	0.6	51
135	Heat stroke leading to acute liver injury & failure: A case series from the Acute Liver Failure Study Group. <i>Liver International</i> , 2017, 37, 509-513.	1.9	48
136	Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid. <i>Hepatology</i> , 2020, 71, 1511-1514.	3.6	48
137	Virological response and safety outcomes in therapy–na–ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. <i>Journal of Hepatology</i> , 2007, 47, 51-59.	1.8	47
138	Neutrophil-to-Lymphocyte Ratio Associates Independently With–Mortality in Hospitalized Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1786-1791.e1.	2.4	47
139	Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. <i>Journal of Viral Hepatitis</i> , 1995, 2, 175-179.	1.0	46
140	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With–Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. <i>Gastroenterology</i> , 2016, 151, 893-901.e1.	0.6	46
141	Development and Pharmacokinetics and Pharmacodynamics of Pegylated Interferon Alfa-2a (40 kD). <i>Seminars in Liver Disease</i> , 2004, 24, 33-38.	1.8	45
142	Coagulopathy in liver disease. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 464-473.	0.3	45
143	Peginterferon alfa–2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub–sets of older and younger HCV genotype 1 patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 724-731.	1.0	43
144	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43

#	ARTICLE	IF	CITATIONS
145	Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2002, 9, 334-339.	1.0	42
146	Underreporting of Liver Transplant Waitlist Removals Due to Death or Clinical Deterioration. <i>Transplantation</i> , 2013, 96, 211-216.	0.5	42
147	T1 ρ -MRI of healthy and fibrotic human livers at 1.5T. <i>Journal of Translational Medicine</i> , 2015, 13, 292.	1.8	42
148	Model for End-Stage Liver Disease Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. <i>Hepatology</i> , 2020, 72, 1747-1757.	3.6	42
149	Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 258-272.	1.9	41
150	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1091-1100.	0.2	41
151	Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 1297-1304.	0.2	39
152	Hepatitis B and C in African Americans: Current Status and Continued Challenges. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 738-748.	2.4	38
153	Hepatitis C Virus Genotypes and Viremia and Hepatocellular Carcinoma in The United States. <i>American Journal of Gastroenterology</i> , 1999, 94, 1619-1626.	0.2	37
154	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , 2019, 71, 486-497.	1.8	37
155	Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis. <i>Seminars in Liver Disease</i> , 2019, 39, 195-208.	1.8	37
156	Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α -2a plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2007, 15, 071007182232001-???	1.0	36
157	COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. <i>Journal of Viral Hepatitis</i> , 2022, 29, 4-20.	1.0	36
158	A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 1012-1018.	1.8	34
159	NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1337-1346.	1.9	34
160	Infections in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 254-270.	0.3	34
161	Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 996-1008.e6.	2.4	33
162	Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. <i>Clinical Transplantation</i> , 2007, 21, 377-384.	0.8	32

#	ARTICLE	IF	CITATIONS
163	Relationship Between Characteristics of Medications and Drug-Induced Liver Disease Phenotype and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1550-1555.	2.4	32
164	HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 113-122.	2.4	32
165	Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1354-1361.	1.1	32
166	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , 2019, 157, 1506-1517.e1.	0.6	32
167	Budd-Chiari syndrome: A single-center experience. <i>World Journal of Gastroenterology</i> , 2014, 20, 16236.	1.4	32
168	Chronic hepatitis C and chronic kidney disease: Advances, limitations and uncharted territories. <i>Journal of Viral Hepatitis</i> , 2017, 24, 442-453.	1.0	31
169	Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1 and 6 in Myanmar: Real-world experience. <i>Journal of Viral Hepatitis</i> , 2017, 24, 927-935.	1.0	31
170	Diagnosis and Management of Overlap Syndromes. <i>Clinics in Liver Disease</i> , 2015, 19, 81-97.	1.0	30
171	SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections. <i>Clinical Liver Disease</i> , 2020, 15, 191-194.	1.0	29
172	Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads. <i>Gastroenterology</i> , 2010, 139, 1972-1983.	0.6	28
173	Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. <i>United European Gastroenterology Journal</i> , 2019, 7, 642-650.	1.6	28
174	Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 559-565.	3.7	27
175	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 2699-2713.	3.6	27
176	Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. <i>Liver Transplantation</i> , 2009, 15, 1010-1020.	1.3	26
177	Factors That Predict Short-term Intensive Care Unit Mortality in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1194-1200.e2.	2.4	26
178	Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage. <i>Transplantation</i> , 2018, 102, 648-655.	0.5	26
179	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. <i>Journal of Hepatology</i> , 2022, 77, 1670-1689.	1.8	26
180	A cut-off serum creatinine value of 1.5 mg/dl for AKI – To be or not to be. <i>Journal of Hepatology</i> , 2015, 62, 741-743.	1.8	25

#	ARTICLE	IF	CITATIONS
181	Acute Liver Failure. Clinics in Liver Disease, 2017, 21, 769-792.	1.0	25
182	Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. Liver Transplantation, 2021, 27, 1343-1347.	1.3	25
183	End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease. Clinical Transplantation, 2014, 28, 205-210.	0.8	24
184	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatology Research, 2017, 47, 1340-1345.	1.8	24
185	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. Journal of Hepatology, 2021, 74, 972-974.	1.8	24
186	Epstein-Barr Virus and Cytomegalovirus Infections of the Liver. Gastroenterology Clinics of North America, 2020, 49, 331-346.	1.0	24
187	Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert Review of Gastroenterology and Hepatology, 2015, 9, 547-558.	1.4	23
188	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS ONE, 2018, 13, e0196908.	1.1	23
189	Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal of Hepatology, 2022, 76, 1100-1108.	1.8	22
190	Transjugular intrahepatic portosystemic shunts in liver transplant recipients. Liver Transplantation, 2014, 20, 130-139.	1.3	21
191	Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?. Journal of Clinical and Experimental Hepatology, 2018, 8, 81-94.	0.4	21
192	Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort. Clinical Gastroenterology and Hepatology, 2022, 20, 2393-2395.e4.	2.4	21
193	Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatology Communications, 2021, 5, 938-946.	2.0	21
194	Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical Gastroenterology and Hepatology, 2022, 20, 458-460.e4.	2.4	21
195	Hepatic encephalopathy and orotic aciduria associated with hepatocellular carcinoma in a noncirrhotic liver. Hepatology, 1988, 8, 78-81.	3.6	20
196	Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver International, 2018, 38, 821-833.	1.9	20
197	Hepatitis B Virus Reactivation. Clinics in Liver Disease, 2020, 24, 317-333.	1.0	20
198	Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clinical Trials, 2012, 9, 102-112.	0.7	19

#	ARTICLE	IF	CITATIONS
199	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 768-776.	1.1	19
200	Electron Microscopic Evidence of Non-A, Non-B Hepatitis Markers and Virus-Like Particles in Immunocompromised Humans. <i>Hepatology</i> , 1984, 4, 628-632.	3.6	18
201	Hepatitis C viraemic organs in solid organ transplantation. <i>Journal of Hepatology</i> , 2021, 74, 716-733.	1.8	18
202	Pharmacologic Management of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2019, 23, 713-736.	1.0	17
203	Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. <i>Contemporary Clinical Trials</i> , 2019, 76, 49-54.	0.8	17
204	Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 304-315.	0.4	17
205	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	3.6	17
206	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2571-2579.	1.1	17
207	Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 124-133.	0.7	17
208	Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 124-33.	0.7	17
209	Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , 2008, 13, 23-30.	0.6	17
210	Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. <i>Clinics in Liver Disease</i> , 2003, 7, 683-714.	1.0	16
211	Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000400.	1.2	16
212	Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1362-1371.	1.0	16
213	High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1186-1199.	1.0	16
214	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 468-476.e11.	2.4	16
215	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1011-1020.	1.3	16
216	Association Between Plasma Level of Galectin-9 and Survival of Patients With Drug-Induced Acute Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 606-612.e3.	2.4	15

#	ARTICLE	IF	CITATIONS
217	Sofosbuvir-Ledipasvir with or without Ribavirin for Chronic Hepatitis C Genotype-1 and 6: Real-World Experience in Vietnam. <i>Antiviral Therapy</i> , 2018, 23, 415-423.	0.6	15
218	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3612-3618.	1.1	15
219	Amebiasis. Current Treatment Options in <i>Gastroenterology</i> , 1999, 2, 97-103.	0.3	14
220	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , 2017, 30, 196-208.	0.8	14
221	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. <i>Hepatology Communications</i> , 2018, 2, 354-363.	2.0	14
222	Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 492-505.	1.9	14
223	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1661-1669.e2.	2.4	14
224	Acute Liver Failure Etiology Is an Independent Predictor of Waitlist Outcome but Not Posttransplantation Survival in a National Cohort. <i>Liver Transplantation</i> , 2022, 28, 39-50.	1.3	14
225	Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 71-80.	0.9	14
226	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	0.8	13
227	A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities. <i>Journal of Hepatology</i> , 2020, 73, 708-709.	1.8	13
228	Transplant center experience influences spontaneous survival and waitlist mortality in acute liver failure: An analysis of the UNOS database. <i>American Journal of Transplantation</i> , 2021, 21, 1092-1099.	2.6	13
229	Inpatient Frailty Assessment Is Feasible and Predicts Nonhome Discharge and Mortality in Decompensated Cirrhosis. <i>Liver Transplantation</i> , 2021, 27, 1711-1722.	1.3	13
230	Response-guided and unguided treatment of chronic hepatitis C. <i>Liver International</i> , 2012, 32, 64-73.	1.9	12
231	In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2389-2397.e2.	2.4	12
232	Hepatocellular carcinoma: Current treatment strategies. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 457-466.	0.3	11
233	Evaluation of nonmalignant liver masses. <i>Current Gastroenterology Reports</i> , 2006, 8, 38-45.	1.1	11
234	Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C-Related Liver Disease. <i>Liver Transplantation</i> , 2018, 24, 1665-1672.	1.3	11

#	ARTICLE	IF	CITATIONS
235	Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ. <i>American Journal of Transplantation</i> , 2019, 19, 2525-2532.	2.6	11
236	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , 2021, 41, 692-704.	1.9	11
237	COVID-19 Vaccine Perceptions Among Patients With Chronic Disease in a Large Gastroenterology and Hepatology Practice. <i>American Journal of Gastroenterology</i> , 2021, 116, 1345-1349.	0.2	11
238	The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , 2022, 28, 560-570.	1.3	11
239	Gene therapy: Practical aspects of implementation. <i>Haemophilia</i> , 2022, 28, 44-52.	1.0	11
240	Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. <i>Cancer</i> , 1994, 74, 1869-1873.	2.0	10
241	Hepatic Manifestations of Lymphoproliferative Disorders. <i>Clinics in Liver Disease</i> , 2019, 23, 293-308.	1.0	10
242	Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2645-2652.	1.1	10
243	Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. <i>JCO Precision Oncology</i> , 2021, 5, 988-1000.	1.5	10
244	A pragmatic outreach pilot to understand and overcome barriers to COVID-19 vaccination in abdominal organ transplant. <i>Transplant Infectious Disease</i> , 2021, 23, e13722.	0.7	10
245	Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. <i>World Journal of Gastroenterology</i> , 2016, 22, 5285.	1.4	10
246	Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1472-1480.	1.9	10
247	The Mucosally-Adherent Rectal Microbiota Contains Features Unique to Alcohol-Related Cirrhosis. <i>Gut Microbes</i> , 2021, 13, 1987781.	4.3	10
248	Spontaneous group B <i>Salmonella enteritidis</i> peritonitis in cirrhotic ascites and acquired immune deficiency syndrome. <i>American Journal of Gastroenterology</i> , 1988, 83, 882-4.	0.2	10
249	On-Treatment HCV RNA in Patients with Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial. <i>Antiviral Therapy</i> , 2016, 21, 541-546.	0.6	9
250	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	2.0	9
251	Black Race Is Associated With Higher Rates of Early-Onset End-Stage Renal Disease and Increased Mortality Following Liver Transplantation. <i>Liver Transplantation</i> , 2021, 27, 1154-1164.	1.3	9
252	Severe Liver Injury. <i>Annals of Internal Medicine</i> , 2001, 135, 550.	2.0	9

#	ARTICLE	IF	CITATIONS
253	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab605.	0.4	9
254	Hepatitis C Virus Infection and Immunomodulatory Therapies. <i>Clinics in Liver Disease</i> , 2009, 13, 391-401.	1.0	8
255	Ribavirin: How Does it Work and is it Still Needed?. <i>Current Hepatitis Reports</i> , 2011, 10, 168-178.	0.3	8
256	Hepatitis E Virus Does Not Contribute to Hepatic Decompensation Among Patients With Advanced Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 896-902.	2.4	8
257	Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 283-293.	0.4	8
258	Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis. <i>Liver Transplantation</i> , 2021, 27, 568-579.	1.3	8
259	Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. <i>World Journal of Gastroenterology</i> , 2016, 22, 9613.	1.4	8
260	Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1169-1178.	1.9	8
261	Dilatation of Biliary Strictures through the Afferent Limb of a Roux-en-Y Choledochojejunostomy in Patients with Sclerosing Cholangitis. <i>World Journal of Surgery</i> , 2001, 25, 1251-1253.	0.8	7
262	Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. <i>Hepatology</i> , 2013, 58, 1181-1184.	3.6	7
263	Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: Results from the national institutes of health mu. <i>Liver Transplantation</i> , 2013, 19, 619-626.	1.3	7
264	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 565-572.e5.	2.4	7
265	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	3.6	7
266	Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1031-1040.e3.	2.4	7
267	Chronic Kidney Disease After Orthotopic Liver Transplantation: Impact of Hepatitis C Infection. <i>Transplantation</i> , 2011, 91, 1245-1249.	0.5	6
268	Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx012.	0.4	6
269	Occult Hepatocellular Carcinoma Associated With Transjugular Intrahepatic Portosystemic Shunts in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021, 27, 1248-1261.	1.3	6
270	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , 2021, 5, 538-547.	2.0	6

#	ARTICLE	IF	CITATIONS
271	Glutathione-S-Transferase M1 null genotype in autoimmune hepatitis. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2080-2083.	1.1	5
272	Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1301-1308.	1.4	5
273	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , 2016, 11, e0151703.	1.1	5
274	Hospitalized Women With Cirrhosis Have More Nonhepatic Comorbidities and Associated Complications Than Men. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3046-3048.	2.4	5
275	Nonpharmacologic Management of Hepatic Encephalopathy. <i>Clinics in Liver Disease</i> , 2020, 24, 243-261.	1.0	5
276	Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. <i>Gastroenterology Clinics of North America</i> , 1995, 24, 923-36.	1.0	5
277	Approach to a Liver Mass. <i>Clinics in Liver Disease</i> , 2009, 13, 193-210.	1.0	4
278	Hormones: A Potential Explanation for Differences in Response Rates to Therapy for Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2011, 140, 776-779.	0.6	4
279	Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 901-909.	1.0	4
280	Letter: retrospective reviews of liver-related case reports allegedly associated with Herbalife present insufficient and inaccurate data – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 754-755.	1.9	4
281	Let's Make a Deal: Shortening the Solid Organ Transplant Waiting Time in Exchange for Transmitting and Treating Hepatitis C Infection in the Era of Safe and Effective Directly Acting Antivirals. <i>Clinical Infectious Diseases</i> , 2018, 66, 293-295.	2.9	4
282	Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys. <i>Clinical Transplantation</i> , 2019, 33, e13494.	0.8	4
283	Large Hepatic Adenomas and Hepatic Adenomatosis: A Multicenter Study of Risk Factors, Interventions, and Complications. <i>American Journal of Gastroenterology</i> , 2022, 117, 1089-1096.	0.2	4
284	Combined surgical and radiologic approach to recurrent cholangitis and intrahepatic pigment stones. <i>Gastroenterology</i> , 1988, 95, 1383-1387.	0.6	3
285	Intensified Peginterferon α -2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 271-279.	1.1	3
286	Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	3
287	Fungal and Parasitic Infections of the Liver. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 379-410.	1.0	3
288	Impact of the Corona Virus Disease 2019 Pandemic on Hepatology Practice and Provider Burnout. <i>Hepatology Communications</i> , 2022, 6, 1236-1247.	2.0	3

#	ARTICLE	IF	CITATIONS
289	When (and When Not) to Treat Patients With HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2644-2647.	2.4	2
290	Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1222-1233.	1.0	2
291	Willingness to participate in research among black patients with liver disease: A national cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 982-993.	1.0	2
292	Prognosis of hospitalized patients with cirrhosis and acute kidney disease. <i>Liver International</i> , 2022, , .	1.9	2
293	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 918-919.	2.4	1
294	The Need for Appropriate Comparisons: A Response to Ravi et al. <i>Gastroenterology</i> , 2017, 153, 332-333.	0.6	1
295	Editorial: leave it unhooked? Possible benefits of ileostomy over ileal pouch-anal anastomosis in patients with ulcerative colitis and primary sclerosing cholangitis in the setting of liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 581-582.	1.9	1
296	Oral Contraceptive-Induced Hepatic Sinusoidal Dilatation and Potential Implications for Living Donor Liver Transplantation: A Reason for Nonuse of Right Lobe Grafts. <i>Liver Transplantation</i> , 2020, 26, 722-725.	1.3	1
297	Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 983-984.	1.9	1
298	Primary Sclerosing Cholangitis: From Pathogenesis to Medical Management. <i>North American Journal of Medicine & Science</i> , 2012, 5, 82.	3.8	1
299	Con: Patients With Acute-on-Chronic Liver Failure Should Not Receive Priority on the Waiting List. <i>Clinical Liver Disease</i> , 2022, 19, 207-212.	1.0	1
300	Hand-assisted laparoscopic microwave coagulation therapy for hepatocellular carcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2002, 16, 717-717.	1.3	0
301	Preface. <i>Clinics in Liver Disease</i> , 2008, 12, xiii-xiv.	1.0	0
302	Management of HBV, HCV, and HDV coinfection. <i>Current Hepatitis Reports</i> , 2009, 8, 111-118.	0.3	0
303	Donation after cardiac death organs for patients with hepatitis C virus: Are we rolling the dice, or are they just as good as any?. <i>Liver Transplantation</i> , 2011, 17, 625-627.	1.3	0
304	Hepatitis C viral infection in patients with cirrhosis. <i>Clinical Liver Disease</i> , 2012, 1, 65-68.	1.0	0
305	Hepatitis C Genotype 3: The Remaining Problem. <i>Current Hepatology Reports</i> , 2015, 14, 267-273.	0.4	0
306	Hepatitis C: Unfolding the Challenges. <i>Gastroenterology Clinics of North America</i> , 2015, 44, xv-xvi.	1.0	0

#	ARTICLE	IF	CITATIONS
307	Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1022-1023.	1.9	0
308	Reply:. <i>Hepatology</i> , 2018, 68, 2046-2048.	3.6	0
309	Letter: direct-acting anti-viral (<sc>DAA</sc>) therapy needs strong safety and efficacy check- authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 235-236.	1.9	0
310	Reply. <i>Liver Transplantation</i> , 2019, 25, 1586-1587.	1.3	0
311	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS-ACO13 HEPAVIH)" <i>Journal of Hepatology</i> , 2020, 72, 592-593.	1.8	0
312	Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients awaiting a liver transplant" <i>Journal of Hepatology</i> , 2020, 73, 985-986.	1.8	0
313	Infections of the Liver and Biliary System. <i>Gastroenterology Clinics of North America</i> , 2020, 49, xv-xvi.	1.0	0
314	Reply to Roussel et al. <i>Clinical Infectious Diseases</i> , 2021, 72, e929-e929.	2.9	0
315	REPLY:. <i>Hepatology</i> , 2021, 74, 2916-2917.	3.6	0
316	Viral Hepatitis: Hepatitis C. , 2017, , 143-163.		0
317	Supplements and Hepatotoxicity. <i>Gastroenterology and Hepatology</i> , 2015, 11, 477-9.	0.2	0
318	Benign Lesions of the Liver. <i>Gastroenterology and Hepatology</i> , 2006, 2, 325-326.	0.2	0
319	Transplantation for chronic hepatitis B and C: strategies for prevention and treatment of recurrent disease. <i>Indian Journal of Gastroenterology</i> , 2001, 20 Suppl 1, C59-63.	0.7	0